H.C. Wainwright raised the firm’s price target on electroCore (ECOR) to $22 from $15 and keeps a Buy rating on the shares after the firm ...

H.C. Wainwright has downgraded Syros Pharmaceuticals (NASDAQ:SYRS) to neutral from buy, citing Tuesday’s announcement that a ...

H.C. Wainwright raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $73 from $61 and keeps a Buy rating on the shares. The ...

Ardelyx (NASDAQ:ARDX) shares were down over 5% after H.C. Wainwright downgraded the rating for the biopharmaceutical firm, ...

H.C. Wainwright downgraded Syros Pharmaceuticals (SYRS) to Neutral from Buy with a price target of $1, down from $6, after ...

H.C. Wainwright reinstated coverage of Opus Genetics (IRD) with a Buy rating and $8 price target The firm believes inherited ...

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

On Wednesday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a decline, ending the day at $1.09 which represents a decrease of $-0.10 or -8.40% from the prior close of $1.19. The stock opened at $1.18 ...

MARA shares down as Q3 earnings miss estimates with lower revenue and adjusted loss, analysts maintain mixed views and price ...

On Wednesday, Fate Therapeutics Inc (FATE) stock saw a decline, ending the day at $2.17 which represents a decrease of $-0.21 or -8.82% from the prior close of $2.38. The stock opened at $2.45 and ...

H.C. Wainwright placed the firm’s Buy rating on Ocuphire Pharma (OCUP) under review saying the acquisition of Opus Genetics starts a new chapter. The views and opinions expressed herein are the ...

H.C. Wainwright initiated coverage of BitFuFu (FUFU) with a Buy rating and $7 price target BitFuFu is a cloud mining service provider, meaning the company hosts bitcoin mining machines in its ...